Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker

Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial

(2020) Masayuki Tahara et al.   LANCET NEUROLOGY

The Brain’s Glymphatic System: Current Controversies

(2020) Humberto Mestre et al.   TRENDS IN NEUROSCIENCES

Blood biomarkers on admission in acute traumatic brain injury: Relations to severity, CT findings and care path in the CENTER-TBI study

(2020) Endre Czeiter et al.   EBioMedicine

Neuromyelitis optica spectrum disorders

(2019) Kazuo Fujihara   CURRENT OPINION IN NEUROLOGY

Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder

(2019) Sean J. Pittock et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

(2019) Bruce A C Cree et al.   LANCET

Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD

(2019) Mitsuru Watanabe et al.   NEUROLOGY

Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder

(2019) Takashi Yamamura et al.   NEW ENGLAND JOURNAL OF MEDICINE

Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders

(2019) Marius Ringelstein et al.   NEUROLOGY

Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study

(2018) Frederike C Oertel et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Neurofilaments as biomarkers in neurological disorders

(2018) Michael Khalil et al.   Nature Reviews Neurology

Serum GFAP as a biomarker for disease severity in multiple sclerosis

(2018) A. Abdelhak et al.   Scientific Reports

Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity

(2018) Heidi Högel et al.   Multiple Sclerosis Journal

The Meningeal Lymphatic System: A New Player in Neurophysiology

(2018) Sandro Da Mesquita et al.   NEURON

Normal-appearing white matter demyelination in neuromyelitis optica spectrum disorder

(2017) I. H. Jeong et al.   EUROPEAN JOURNAL OF NEUROLOGY

Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study

(2017) Mark A Agius et al.   Multiple Sclerosis Journal

Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study

(2017) Mark A Agius et al.   Multiple Sclerosis Journal

Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder

(2016) In Hye Jeong et al.   JOURNAL OF NEUROLOGY

Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders

(2016) Valentina Damato et al.   JAMA Neurology

Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies

(2016) Ding Chen et al.   Journal of Clinical Medicine

Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease

(2015) Axel Petzold   BRAIN RESEARCH

Placebo-controlled study in neuromyelitis optica—Ethical and design considerations

(2015) Bruce AC Cree et al.   Multiple Sclerosis Journal

Placebo-controlled study in neuromyelitis optica—Ethical and design considerations

(2015) Bruce AC Cree et al.   Multiple Sclerosis Journal

The Pathology of an Autoimmune Astrocytopathy: Lessons Learned from Neuromyelitis Optica

(2013) Claudia F. Lucchinetti et al.   BRAIN PATHOLOGY

Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks

(2013) Akiyuki Uzawa et al.   CLINICA CHIMICA ACTA

Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)

(2013) Corinna Trebst et al.   JOURNAL OF NEUROLOGY

Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study

(2013) Sean J Pittock et al.   LANCET NEUROLOGY

Visual evoked potentials in neuromyelitis optica and its spectrum disorders

(2013) Marius Ringelstein et al.   Multiple Sclerosis Journal

Elevated Levels of Serum Glial Fibrillary Acidic Protein Breakdown Products in Mild and Moderate Traumatic Brain Injury Are Associated With Intracranial Lesions and Neurosurgical Intervention

(2011) Linda Papa et al.   ANNALS OF EMERGENCY MEDICINE

Glial but not axonal protein biomarkers as a new supportive diagnostic criteria for Devic neuromyelitis optica? Preliminary results on 188 patients with different neurological diseases

(2010) A. Petzold et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations

(2010) David M Rissin et al.   NATURE BIOTECHNOLOGY

Astrocytes: biology and pathology

(2009) Michael V. Sofroniew et al.   ACTA NEUROPATHOLOGICA

Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo

(2009) Monika Bradl et al.   ANNALS OF NEUROLOGY

Intrathecal pathogenic anti–aquaporin-4 antibodies in early neuromyelitis optica

(2009) Jeffrey L. Bennett et al.   ANNALS OF NEUROLOGY

Dysfunctions of neuronal and glial intermediate filaments in disease

(2009) Ronald K.H. Liem et al.   JOURNAL OF CLINICAL INVESTIGATION

Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker

(2009) T Misu et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

A Prominent Elevation of Glial Fibrillary Acidic Protein in the Cerebrospinal Fluid during Relapse in Neuromyelitis Optica

(2008) Rina Takano et al.   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE